Ozempic is generally safe when used as prescribed for its approved conditions. It has been FDA-approved since 2017, and large clinical trials involving tens of thousands of participants have established a well-documented safety profile. That said, “safe” comes with important caveats: most people experience at least some side effects, a few rare but serious risks exist, and the drug carries an FDA boxed warning related to thyroid tumors found in animal studies.
What Ozempic Is Approved For
Ozempic (semaglutide) is a weekly injection approved for three specific uses in adults with type 2 diabetes: improving blood sugar control alongside diet and exercise, reducing the risk of major cardiovascular events like heart attack and stroke in people with established heart disease, and protecting kidney function in people with chronic kidney disease. It is not FDA-approved for weight loss on its own, though a higher-dose version of the same drug (Wegovy) is. Many people use Ozempic off-label for weight management, which changes the risk-benefit calculation since the drug wasn’t specifically tested and approved for that purpose in otherwise healthy individuals.
Common Side Effects
The most frequent complaints are gastrointestinal: nausea, vomiting, diarrhea, abdominal pain, and constipation. These affect a significant number of users. In clinical trials, roughly 31% of people on the standard 1 mg dose experienced GI side effects, and that number climbed to 34% at the higher 2 mg dose. For most people, these symptoms are worst during the first few weeks and ease as the body adjusts.
The GI side effects are uncomfortable but rarely dangerous. In trials, only about 3% to 4% of people on Ozempic discontinued the drug because of stomach-related problems, compared to 0.4% on placebo. Severe GI reactions occurred in under 1% of participants. Starting at a low dose and increasing gradually, as the prescribing protocol recommends, helps minimize these effects.
The Thyroid Cancer Warning
Ozempic carries the FDA’s most serious label, a boxed warning, for the risk of thyroid C-cell tumors. In rodent studies, semaglutide caused thyroid tumors at doses comparable to what humans take, and the risk increased with higher doses and longer treatment. Whether this translates to humans remains unknown. The biology of thyroid C-cells differs between rodents and people, so the relevance is genuinely uncertain rather than just understudied.
Because of this uncertainty, Ozempic is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or a genetic condition called Multiple Endocrine Neoplasia syndrome type 2. If you have either of these in your background, this drug is off the table entirely.
Cardiovascular Benefits
One of the strongest safety signals for Ozempic is actually a positive one. In a large trial following participants for an average of nearly four years, semaglutide reduced the risk of major cardiovascular events (heart attack, stroke, or cardiovascular death) by 14% compared to placebo. This benefit held up regardless of what other diabetes medications people were taking. For people with type 2 diabetes and existing heart disease, this cardiovascular protection is a meaningful part of the drug’s safety-benefit profile.
Pancreatitis Risk
There has been ongoing concern about whether GLP-1 drugs like Ozempic increase the risk of acute pancreatitis, a painful and potentially dangerous inflammation of the pancreas. The evidence is mixed. Large cardiovascular outcome trials and phase 3 studies of semaglutide have not found a statistically significant increase in pancreatic events compared to placebo. However, other analyses have pointed toward a possible elevated risk, and rare but serious cases have been reported, including fatal ones. The follow-up periods in major trials may not be long enough to fully capture this risk.
Symptoms of pancreatitis include severe, persistent abdominal pain that often radiates to the back, sometimes with nausea and vomiting. If you experience this kind of pain while on Ozempic, it needs immediate medical attention.
Gastroparesis and Stomach Emptying
Ozempic works partly by slowing how fast food leaves your stomach, which helps control blood sugar spikes and makes you feel full longer. In some people, this effect goes too far. Reports of gastroparesis, where the stomach essentially stops emptying normally, have drawn attention. The exact prevalence is still unknown, but one study of healthy volunteers taking GLP-1 drugs found delayed gastric emptying in 50% of participants.
For most users, slower stomach emptying is mild and contributes to the intended effects of the drug. But in a subset of people, it can cause persistent nausea, bloating, and vomiting that doesn’t resolve with time. This risk is worth discussing with your prescriber, especially if you already have conditions that affect stomach motility.
Muscle Loss During Weight Loss
When people lose weight on Ozempic, not all of it comes from fat. A systematic review of six clinical trials covering over 1,500 adults found that while fat loss accounted for the majority of weight reduction, lean mass (which includes muscle) decreased by anywhere from nearly 0% to 40% of total weight lost, depending on the study. Larger trials tended to show more noticeable muscle loss.
There is a silver lining in the data: even when people lost some muscle in absolute terms, their ratio of lean mass to total body mass actually improved, meaning they became proportionally leaner. Still, losing muscle matters, especially for older adults where muscle loss accelerates age-related frailty. Resistance training and adequate protein intake during treatment can help preserve muscle, and many prescribers now recommend both as part of an Ozempic regimen.
Kidney Function
Ozempic’s relationship with the kidneys is nuanced. On one hand, the drug is now FDA-approved specifically to protect kidney function in people with type 2 diabetes and chronic kidney disease. On the other hand, dehydration from persistent vomiting or diarrhea can stress the kidneys, and cases of acute kidney injury have been reported in the context of severe GI side effects. The kidney risk isn’t from the drug itself so much as from the fluid loss that its side effects can cause. Staying well-hydrated is important, especially during the dose-escalation phase when nausea tends to peak. Your doctor may order periodic blood or urine tests to keep tabs on kidney function while you’re on treatment.
Eye Health
Early concerns surfaced about whether semaglutide could worsen diabetic retinopathy, a diabetes-related eye condition. A large meta-analysis of 78 trials involving over 73,000 participants found no increased risk. Semaglutide did not raise or lower the odds of eye disorders or diabetic retinopathy. That said, rapid improvements in blood sugar control from any treatment can temporarily worsen existing retinopathy, so if you already have diabetic eye disease, your doctor may want to monitor your eyes more closely during treatment.
What Ongoing Monitoring Looks Like
If you’re on Ozempic for type 2 diabetes, expect your doctor to check your A1C (a measure of average blood sugar over two to three months) at least twice a year, along with regular at-home blood sugar monitoring. Depending on your health profile, they may also order periodic kidney function tests and eye exams. This level of monitoring is standard for diabetes management in general, not unique to Ozempic, but it becomes especially important given the drug’s effects on multiple body systems.